Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Licette C Y Liu

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|June 23, 2015
Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney diseaseLicette C Y Liu, Elise Schutte, Ron T Gansevoort, et al.
The Canadian Journal of Cardiology|February 26, 2014
A novel approach to drug development in heart failure: towards personalized medicineLicette C Y Liu, Adriaan A Voors, Mattia A E Valente, et al.
European Journal of Heart Failure|January 28, 2014
Heart failure highlights in 2012-2013Licette C Y Liu, Kevin Damman, Eric Lipsic, et al.
European Journal of Heart Failure|November 23, 2016
Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertensionLicette C Y Liu, Yoran M Hummel, Peter van der Meer, et al.
Journal of Cardiac Failure|July 25, 2017
Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO<sub>2</sub> Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary HypertensionSebastiaan H C Klaassen, Licette C Y Liu, Yoran M Hummel, et al.
European Journal of Heart Failure|February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fractionAdriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
European Heart Journal|July 19, 2015
Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trialElke S Hoendermis, Licette C Y Liu, Yoran M Hummel, et al.
European Journal of Heart Failure|October 7, 2017
Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurementsYoran M Hummel, Licette C Y Liu, Carolyn S P Lam, et al.
European Journal of Heart Failure|May 6, 2011
Vitamin D status and outcomes in heart failure patientsLicette C Y Liu, Adriaan A Voors, Dirk J van Veldhuisen, et al.
JACC. Heart Failure|December 27, 2016
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial VolumeCarolyn S P Lam, Michiel Rienstra, Wan Ting Tay, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|June 23, 2015
Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney diseaseLicette C Y Liu, Elise Schutte, Ron T Gansevoort, et al.
The Canadian Journal of Cardiology|February 26, 2014
A novel approach to drug development in heart failure: towards personalized medicineLicette C Y Liu, Adriaan A Voors, Mattia A E Valente, et al.
European Journal of Heart Failure|January 28, 2014
Heart failure highlights in 2012-2013Licette C Y Liu, Kevin Damman, Eric Lipsic, et al.
European Journal of Heart Failure|November 23, 2016
Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertensionLicette C Y Liu, Yoran M Hummel, Peter van der Meer, et al.
Journal of Cardiac Failure|July 25, 2017
Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO<sub>2</sub> Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary HypertensionSebastiaan H C Klaassen, Licette C Y Liu, Yoran M Hummel, et al.
European Journal of Heart Failure|February 7, 2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fractionAdriaan A Voors, Mauro Gori, Licette C Y Liu, et al.
European Heart Journal|July 19, 2015
Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trialElke S Hoendermis, Licette C Y Liu, Yoran M Hummel, et al.
European Journal of Heart Failure|October 7, 2017
Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurementsYoran M Hummel, Licette C Y Liu, Carolyn S P Lam, et al.
European Journal of Heart Failure|May 6, 2011
Vitamin D status and outcomes in heart failure patientsLicette C Y Liu, Adriaan A Voors, Dirk J van Veldhuisen, et al.
JACC. Heart Failure|December 27, 2016
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial VolumeCarolyn S P Lam, Michiel Rienstra, Wan Ting Tay, et al.
Pageof 2